BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...Ataxia telangiectasia and Rad3 related BRCA1 - Breast cancer 1 early onset CCNE1 (CCNE) - Cyclin E1...
BioCentury | Sep 4, 2019
Finance

Repare readies for clinic with Cowen-led $82M B round

...Ataxia telangiectasia mutated; ATR (FRP1) - Ataxia telangiectasia and Rad3 related; CCNE1 (CCNE) - Cyclin E1...
...Eaton, Staff Writer Cowen Healthcare Investments Repare Therapeutics Inc. Ataxia telangiectasia and Rad3 related (ATR) (FRP1) Ataxia telangiectasia mutated (ATM) Cyclin E1...
BioCentury | Jun 28, 2019
Translation in Brief

Banking on biomarkers for synthetic lethality

...Ataxia telangiectasia mutated; ATR (FRP1) - Ataxia telangiectasia and Rad3 related; CCNE1 (CCNE) - Cyclin E1...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

...expression. Next steps could include identifying and testing CCNE1/CCNE2 inhibitors in liver cancer models. TARGET/MARKER/PATHWAY: Cyclin E1...
...16, 2018 doi:10.1073/pnas.1711477115 CONTACT: Piotr Sicinski, Dana-Farber Cancer Institute, Boston, Mass. email: peter_sicinski@dfci.harvard.edu Michael Leviten Dana-Farber Cancer Institute Cyclin E1...
BioCentury | Mar 27, 2008
Distillery Therapeutics

This Week in Therapeutics

...Publication and contact information Cancer Cancer Hedgehog (Hh); Smoothened (Smo); MDM2; p53; cyclin D1 (CCND1); cyclin E1...
Items per page:
1 - 5 of 5